
Today’s health briefing covers the start of an Ebola vaccine trial in the Democratic Republic of Congo, a second Ebola death in Kenya, plans to use artificial intelligence on prostate cancer scans in England, the first known human infection with Shamonda virus, and a dispute over how measles deaths are reported in the United States.
Ebola vaccine trial begins in the Democratic Republic of Congo
The first clinical trial of an Ebola vaccine during the current outbreak in the Democratic Republic of Congo began on Friday in Bunia, capital of the north-eastern Ituri province and the centre of the epidemic. The World Health Organization’s director-general, Tedros Adhanom Ghebreyesus, said the first volunteers had been vaccinated in the trial, named Tumaini, the Swahili word for hope. The country’s worst Ebola outbreak on record has now passed 9,700 cases, with more than 4,600 deaths.
No vaccine or treatment has been approved for the Bundibugyo species of the virus driving the epidemic, so the trial will first test Ervebo, a vaccine licensed against the more common Zaire strain, to see whether it offers any cross-protection. Two vaccines designed specifically for Bundibugyo, one from the University of Oxford and an mRNA shot from Moderna, are expected to join soon. The trial will vaccinate rings of high-risk contacts and include pregnant women and children aged 12 and over.
Bundibugyo virus is closely related to the Zaire species and takes its name from the town in western Uganda where it was first discovered. Before this year it caused Ebola outbreaks in 2007 and 2012, and the 2026 epidemic is the fastest-growing Ebola outbreak on record. Congo declared its 17th outbreak of the disease on 15 May, and the WHO declared a public health emergency of international concern two days later. Across the continent, the disease has claimed upwards of 15,000 lives in the last 50 years.
Kenya records a second death in its first Ebola outbreak
Kenya has recorded its second death from Ebola during the first outbreak of the disease in the country. The health ministry said a 65-year-old woman, a close relative of the first patient, died on Friday evening while in quarantine, after receiving supportive care at an infectious disease unit in Nairobi. Seven other patients are being treated at two isolation facilities, and the ministry said all cases belong to a single cluster, with no sign of spread in the community and no new infections in its latest update.
Kenya’s first victim, who died on 5 October, was a man who had travelled from Congo through Uganda before falling gravely ill in Nairobi. Those still in treatment include three of his relatives, three health workers and a hospital cleaner. Some contacts who finish the 21-day quarantine are due to start going home on Saturday. Kenya has tightened checks on travellers from Congo and nine other high-risk countries, while Uganda has stopped people who were in Congo from transiting through it. A doctors’ union has warned of staff shortages at entry points.
Ebola is a viral haemorrhagic fever that spreads through direct contact with body fluids, such as blood or vomit, or with items recently contaminated by them. Symptoms usually begin between two days and three weeks after infection, starting with fever, sore throat, muscle pain and headaches, followed by vomiting and diarrhoea. Outbreaks have had death rates of between 25 and 90%, averaging around 50%. The disease was first reported in 1976, and the largest outbreak so far was the 2013–16 epidemic in West Africa.
AI tools to help read prostate cancer scans across the NHS in England
Artificial intelligence software is to be trialled across the NHS in England to help doctors spot prostate cancer on MRI scans, under draft guidance from the National Institute for Health and Care Excellence. The health spending watchdog recommended five tools, which will be tested for two years to gather more evidence on how they perform. The systems highlight areas of a prostate scan where cancer may be present, and the institute said they could act as an extra pair of eyes for radiologists.
Demand for prostate MRIs has grown because scans are now routinely used before biopsies, adding pressure on radiology teams already short of staff. Peter Johnson, the NHS national clinical director for cancer, said a radiologist would still check every scan, so the technology supports staff rather than replacing them. An independent committee said the tools could make readings more accurate and consistent, though more evidence is needed from routine practice. Prostate Cancer UK said the change could give men faster answers, including those found to be clear.
Around 68,000 men are diagnosed with prostate cancer in the UK every year, and it is the most common cancer in England. Traditionally, a raised result on a PSA blood test led to a biopsy that took tissue from across the prostate without knowing whether a particular area looked suspicious. Under current international practice, patients are usually sent for a detailed MRI scan first, so many men with a clear or low-risk result can avoid a biopsy altogether, while suspicious areas can be sampled more precisely.
First known human Shamonda virus infection confirmed in France
A man in France has become the first person known to have been infected with Shamonda virus, a livestock disease carried by biting midges that spread among European cattle this summer. The patient, aged in his sixties, had leukaemia and was severely immunocompromised. He died on 9 October in a hospital in Lyon, 16 days after developing neurological symptoms including vision loss and confusion. French authorities announced the case on 22 October, calling it exceptional and saying they saw no risk to the general public.
The man lived in a rural part of the Rhône-Alpes region where the virus had been detected in cattle, and was most likely infected through a midge bite, although contaminated food or a transfusion have not yet been ruled out. Researchers say the risk of spread between people is low, since there is no evidence that the virus passes from one person to another. Since the summer it has been found in animals in a dozen countries, after first appearing in southern Germany, Switzerland and eastern France.
Shamonda was first isolated from cattle in Nigeria in 1965 and belongs to a group of viruses called orthobunyaviruses, for which there are no vaccines or antiviral treatments. A relative, Oropouche virus, causes a tropical fever spread by midges and mosquitoes that is endemic to the Amazon basin. In 2024 Oropouche infected upwards of 16,000 people in the Americas and caused its first recorded deaths, and an outbreak in Brazil that year saw the virus pass from pregnant women to their unborn babies.
US health agency declines to name the state of a new measles death
The US Centers for Disease Control and Prevention added a third measles death to its national dashboard on Wednesday, but declined to say in which state it occurred, citing privacy laws. Experts said there were no real privacy concerns in naming a state and that the information matters as the outbreak speeds up. Confirmed cases this year grew by 8% in one week to 4,410, nearly double last year’s total. Pennsylvania alone has reported six deaths, five of them confirmed and the latest still under investigation.
In September the agency switched to reporting deaths through the National Center for Health Statistics, which usually does not identify locations when few deaths have occurred, instead of a faster surveillance system that names the state. It has not given a clear reason for the change. Law professor Dorit Reiss said the agency was being less open than before, while infectious diseases physician Paul Offit warned that adult cases, such as a 39-year-old woman in Franklin County who died of a heart complication, may be undercounted.
Measles was declared eliminated from the United States in 2000, but it keeps being reintroduced, especially by unvaccinated travellers returning from abroad, and anti-vaccination sentiment has fuelled new outbreaks. An unvaccinated person exposed to the virus has a 95% chance of infection, while two doses of the vaccine, given at least one month apart, are 97% effective at preventing the disease. In 2025 the CDC reported 2,289 confirmed cases, and by July 2026 this year was already the worst for measles in more than three decades.